Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 1/2019

01-02-2019 | Review

Cell-free DNA in cancer: current insights

Authors: Heidi Fettke, Edmond M. Kwan, Arun A. Azad

Published in: Cellular Oncology | Issue 1/2019

Login to get access

Abstract

Background

The field of liquid biopsies in oncology is rapidly expanding, with the application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of precision medicine. Compared with traditional clinical and radiographic tumour monitoring methods, the analysis of ctDNA provides a minimally-invasive and technically feasible approach to assess temporal and spatial molecular evolutions of the tumour landscape. The constantly advancing technological platforms available for ctDNA extraction and analysis allow greater analytical sensitivities than ever before. The potential translational impact of ctDNA as a blood-based biomarker for the identification, characterization and monitoring of cancer has been demonstrated in numerous proof-of-concept studies, with ctDNA analysis beginning to be applied clinically across multiple facets of oncology.

Conclusions

In this review we discuss the biology, recent advancements, technical considerations and clinical implications of ctDNA in the context of cancer, and highlight important challenges and future directions for the integration of ctDNA into standardised patient care.
Literature
1.
2.
N. Krishnamurthy, E. Spencer, A. Torkamani, L. Nicholson, Liquid biopsies for cancer: Coming to a patient near you. J Clin Med 6, 3 (2017)CrossRefPubMedCentral
3.
M.J. Overman, J. Modak, S. Kopetz, R. Murthy, J.C. Yao, M.E. Hicks, J.L. Abbruzzese, A.L. Tam, Use of research biopsies in clinical trials: Are risks and benefits adequately discussed? J Clin Oncol 31, 17–22 (2013)CrossRefPubMed
4.
P.A. VanderLaan, N. Yamaguchi, E. Folch, D.H. Boucher, M.S. Kent, S.P. Gangadharan, A. Majid, M.A. Goldstein, M.S. Huberman, O.N. Kocher, D.B. Costa, Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 84, 39–44 (2014)CrossRefPubMed
5.
S.Q. Wong, J. Li, A.Y.C. Tan, R. Vedururu, J.-M.B. Pang, H. Do, J. Ellul, K. Doig, A. Bell, G.A. McArthur, S.B. Fox, D.M. Thomas, A. Fellowes, J.P. Parisot, A. Dobrovic, Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genet 7, 23 (2014)
6.
7.
R. Catarino, M.M. Ferreira, H. Rodrigues, A. Coelho, A. Nogal, A. Sousa, R. Medeiros, Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 27, 415–421 (2008)CrossRefPubMed
8.
N. Hjortholm, E. Jaddini, K. Hałaburda, E. Snarski, Strategies of pain reduction during the bone marrow biopsy. Ann Hematol Oncol 92, 145–149 (2013)CrossRef
9.
J.M. Hemmer, J.C. Kelder, H.P.M. van Heesewijk, Stereotactic large-core needle breast biopsy: Analysis of pain and discomfort related to the biopsy procedure. Eur Radiol 18, 351–354 (2008)CrossRefPubMed
10.
11.
12.
M. Jamal-Hanjani, G.A. Wilson, S. Horswell, R. Mitter, O. Sakarya, T. Constantin, R. Salari, E. Kirkizlar, S. Sigurjonsson, R. Pelham, S. Kareht, B. Zimmermann, C. Swanton, Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol 27, 862–867 (2016)CrossRefPubMed
13.
M. Murtaza, S.J. Dawson, K. Pogrebniak, O.M. Rueda, E. Provenzano, J. Grant, S.F. Chin, D.W. Tsui, F. Marass, D. Gale, H.R. Ali, P. Shah, T. Contente-Cuomo, H. Farahani, K. Shumansky, Z. Kingsbury, S. Humphray, D. Bentley, S.P. Shah, M. Wallis, N. Rosenfeld, C. Caldas, Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun 6, 8760 (2015)CrossRefPubMed
14.
O. Eikrem, C. Beisland, K. Hjelle, A. Flatberg, A. Scherer, L. Landolt, T. Skogstrand, S. Leh, V. Beisvag, H.P. Marti, Transcriptome sequencing (rnaseq) enables utilization of formalin-fixed, paraffin-embedded biopsies with clear cell renal cell carcinoma for exploration of disease biology and biomarker development. PloS One 11, e0149743 (2016)CrossRefPubMedPubMedCentral
15.
G. Siravegna, S. Marsoni, S. Siena, A. Bardelli, Integrating liquid biopsies into the management of cancer. Nature Rev Clin Oncol 14, 531–548 (2017)CrossRef
16.
R. Govindan, L. Ding, M. Griffith, J. Subramanian, N.D. Dees, K.L. Kanchi, C.A. Maher, R. Fulton, L. Fulton, J. Wallis, K. Chen, J. Walker, S. McDonald, R. Bose, D. Ornitz, D. Xiong, M. You, D.J. Dooling, M. Watson, E.R. Mardis, R.K. Wilson, Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121–1134 (2012)CrossRefPubMedPubMedCentral
17.
18.
F.R. Harris, I.V. Kovtun, J. Smadbeck, F. Multinu, A. Jatoi, F. Kosari, K.R. Kalli, S.J. Murphy, G.C. Halling, S.H. Johnson, M.C. Liu, A. Mariani, G. Vasmatzis, Quantification of somatic chromosomal rearrangements in circulating cell-free DNA from ovarian cancers. Sci Rep 6, 29831 (2016)CrossRefPubMedPubMedCentral
19.
J. Li, R.L. Dittmar, S. Xia, H. Zhang, M. Du, C.C. Huang, B.R. Druliner, L. Boardman, L. Wang, Cell-free DNA copy number variations in plasma from colorectal cancer patients. Mol Oncol 11, 1099–1111 (2017)CrossRefPubMedPubMedCentral
20.
R. Casadonte, R.M. Caprioli, Proteomic analysis of formalin-fixed paraffin embedded tissue by maldi imaging mass spectrometry. Nat Protoc 6, 1695–1709 (2011)CrossRefPubMedPubMedCentral
21.
M. Møller, S.H. Strand, K. Mundbjerg, G. Liang, I. Gill, C. Haldrup, M. Borre, S. Høyer, T.F. Ørntoft, K.D. Sørensen, Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. Sci Rep 7, 40636 (2017)CrossRefPubMedPubMedCentral
22.
23.
24.
L. Kubiczkova-Besse, D. Drandi, L. Sedlarikova, S. Oliva, M. Gambella, P. Omedè, Z. Adam, L. Pour, S. Sevcikova, M. Boccadoro, A. Palumbo, R. Hajek, Cell-free DNA for minimal residual disease monitoring in multiple myeloma patients. Blood 124, 3423–3423 (2014)
25.
P. Mandel, P. Metais, Les acides nucléiques du plasma sanguin chez l'homme. Comptes Rendus des Séances de la Société de Biologie et de Ses Filiales 142, 241–243 (1948)PubMed
26.
N. Nair, O. Camacho-Vanegas, D. Rykunov, M. Dashkoff, S.C. Camacho, C.A. Schumacher, J.C. Irish, T.T. Harkins, E. Freeman, I. Garcia, E. Pereira, S. Kendall, R. Belfer, T. Kalir, R. Sebra, B. Reva, P. Dottino, J.A. Martignetti, Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer: A prospective cross-sectional study. PLoS Medicine 13, e1002206 (2016)CrossRefPubMedPubMedCentral
27.
I. Botezatu, O. Serdyuk, G. Potapova, V. Shelepov, R. Alechina, Y. Molyaka, V. Ananev, I. Bazin, A. Garin, M. Narimanov, V. Knysh, H. Melkonyan, S. Umansky, A. Lichtenstein, Genetic analysis of DNA excreted in urine: A new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 46, 1078–1084 (2000)PubMed
28.
S.K. Mithani, I.M. Smith, S. Zhou, A. Gray, W.M. Koch, A. Maitra, J.A. Califano, Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer. Clin Can Res 13, 7335–7340 (2007)CrossRef
29.
J.D. Krimmel, M.W. Schmitt, M.I. Harrell, K.J. Agnew, S.R. Kennedy, M.J. Emond, L.A. Loeb, E.M. Swisher, R.A. Risques, Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic tp53 mutations in noncancerous tissues. Proc Natl Acad Sci U S A 113, 6005–6010 (2016)CrossRefPubMedPubMedCentral
30.
J.C.M. Wan, C. Massie, J. Garcia-Corbacho, F. Mouliere, J.D. Brenton, C. Caldas, S. Pacey, R. Baird, N. Rosenfeld, Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer 17, 223–238 (2017)CrossRefPubMed
31.
M. Stroun, J. Lyautey, C. Lederrey, A. Olson-Sand, P. Anker, About the possible origin and mechanism of circulating DNA. Clinica Chimica Acta 313, 139–142 (2001)CrossRef
32.
D.L. Peters, P.J. Pretorius, Origin, translocation and destination of extracellular occurring DNA — a new paradigm in genetic behaviour. Clinica Chimica Acta 412, 806–811 (2011)CrossRef
33.
R. Lehmann-Werman, D. Neiman, H. Zemmour, J. Moss, J. Magenheim, A. Vaknin-Dembinsky, S. Rubertsson, B. Nellgård, K. Blennow, H. Zetterberg, K. Spalding, M.J. Haller, C.H. Wasserfall, D.A. Schatz, C.J. Greenbaum, C. Dorrell, M. Grompe, A. Zick, A. Hubert, M. Maoz, V. Fendrich, D.K. Bartsch, T. Golan, S.A. Ben Sasson, G. Zamir, A. Razin, H. Cedar, A.M.J. Shapiro, B. Glaser, R. Shemer, Y. Dor, Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci U S A 113,E1826-E1834 (2016)
34.
S. Breitbach, S. Tug, S. Helmig, D. Zahn, T. Kubiak, M. Michal, T. Gori, T. Ehlert, T. Beiter, P. Simon, Direct quantification of cell-free, circulating DNA from unpurified plasma. PloS One 9, e87838 (2014)CrossRefPubMedPubMedCentral
35.
F. Mouliere, S. El Messaoudi, D. Pang, A. Dritschilo, A.R. Thierry, Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol 8, 927–941 (2014)CrossRefPubMedPubMedCentral
36.
W. Yao, C. Mei, X. Nan, L. Hui, Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study. Gene 590, 142–148 (2016)CrossRefPubMed
37.
Y.M.D. Lo, J. Zhang, T.N. Leung, T.K. Lau, A.M.Z. Chang, N.M. Hjelm, Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64, 218–224
38.
39.
A.N. Butt, R. Swaminathan, Overview of circulating nucleic acids in plasma/serum. Ann N Y Acad Sci 1137, 236–242 (2008)CrossRefPubMed
40.
S. Volik, M. Alcaide, R.D. Morin, C. Collins, Cell-free DNA (cfdna): Clinical significance and utility in cancer shaped by emerging technologies. Mol Cancer Res 14, 898–908 (2016)CrossRefPubMed
41.
S.A. Leon, B. Shapiro, D.M. Sklaroff, M.J. Yaros, Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37, 646–650 (1977)PubMed
42.
G.D. Sorenson, D.M. Pribish, F.H. Valone, V.A. Memoli, D.J. Bzik, S.L. Yao, Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers 3, 67–71 (1994)
43.
S. Jahr, H. Hentze, S. Englisch, D. Hardt, F.O. Fackelmayer, R.-D. Hesch, R. Knippers, DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61, 1659–1665 (2001)PubMed
44.
H.R. Underhill, J.O. Kitzman, S. Hellwig, N.C. Welker, R. Daza, D.N. Baker, K.M. Gligorich, R.C. Rostomily, M.P. Bronner, J. Shendure, Fragment length of circulating tumor DNA. PLoS Genetics 12, e1006162 (2016)CrossRefPubMedPubMedCentral
45.
A.R. Thierry, F. Mouliere, C. Gongora, J. Ollier, B. Robert, M. Ychou, M. Del Rio, F. Molina, Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 38, 6159–6175 (2010)CrossRefPubMedPubMedCentral
46.
47.
C. Tetta, E. Ghigo, L. Silengo, M.C. Deregibus, G. Camussi, Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine 44, 11–19 (2013)CrossRefPubMed
48.
E.S. Morozkin, P.P. Laktionov, E.Y. Rykova, O.E. Bryzgunova, V.V. Vlassov, Release of nucleic acids by eukaryotic cells in tissue culture. Nucleosides, Nucleotides and Nucleic Acids 23, 927–930 (2004)CrossRefPubMed
49.
M. Abolhassani, J. Tillotson, J. Chiao, Characterization of the release of DNA by a human leukemia-cell line hl-60. Int J Oncol 4, 417–421 (1994)PubMed
50.
A.J. Bronkhorst, J.F. Wentzel, J. Aucamp, E. van Dyk, L. du Plessis, P.J. Pretorius, Characterization of the cell-free DNA released by cultured cancer cells. Biochimica et Biophysica Acta 1863, 157–165 (2016)CrossRefPubMed
51.
J.A. Collins, C.A. Schandl, K.K. Young, J. Vesely, M.C. Willingham, Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem 45, 923–934 (1997)CrossRefPubMed
52.
M. Beranek, I. Sirak, M. Vosmik, J. Petera, M. Drastikova, V. Palicka, Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer. Acta Medica (Hradec Kralove) 59, 54–58 (2016)CrossRef
53.
M. Peng, C. Chen, A. Hulbert, M.V. Brock, F. Yu, Non-blood circulating tumor DNA detection in cancer. Oncotarget 8, 69162–69173 (2017)PubMedPubMedCentral
54.
M.S. Gordon, Managing anemia in the cancer patient: Old problems, future solutions. Oncologist 7, 331–341 (2002)CrossRefPubMed
55.
D.A. Ahlquist, W.R. Taylor, D.W. Mahoney, H. Zou, M. Domanico, S.N. Thibodeau, L.A. Boardman, B.M. Berger, G.P. Lidgard, The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 10, 272–277 (2012)CrossRefPubMed
56.
A. Castagnaro, E. Marangio, A. Verduri, A. Chetta, R. D'Ippolito, M. Del Donno, D. Olivieri, G. Di Cola, Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. Exp Lung Res 33, 289–301 (2007)CrossRefPubMed
57.
L. De Mattos-Arruda, R. Mayor, C.K. Ng, B. Weigelt, F. Martinez-Ricarte, D. Torrejon, M. Oliveira, A. Arias, C. Raventos, J. Tang, E. Guerini-Rocco, E. Martinez-Saez, S. Lois, O. Marin, X. de la Cruz, S. Piscuoglio, R. Towers, A. Vivancos, V. Peg, S. Ramon y Cajal, J. Carles, J. Rodon, M. Gonzalez-Cao, J. Tabernero, E. Felip, J. Sahuquillo, M.F. Berger, J. Cortes, J.S. Reis-Filho, J. Seoane, Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6, 8839 (2015)CrossRefPubMedPubMedCentral
58.
E.C. Hung, R.W. Chiu, Y.M. Lo, Detection of circulating fetal nucleic acids: A review of methods and applications. J Clin Pathol 62, 308–313 (2009)CrossRefPubMed
59.
J. Jen, L. Wu, D. Sidransky, An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann N Y Acad Sci 906, 8–12 (2000)CrossRefPubMed
60.
T.H. Lee, L. Montalvo, V. Chrebtow, M.P. Busch, Quantitation of genomic DNA in plasma and serum samples: Higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41, 276–282 (2001)CrossRefPubMed
61.
A.J. Bronkhorst, J. Aucamp, P.J. Pretorius, Cell-free DNA: Preanalytical variables. Clinica Chimica Acta 450, 243–253 (2015)CrossRef
62.
H. Markus, T. Contente-Cuomo, M. Farooq, W.S. Liang, M.J. Borad, S. Sivakumar, S. Gollins, N.L. Tran, H.D. Dhruv, M.E. Berens, A. Bryce, A. Sekulic, A. Ribas, J.M. Trent, P.M. LoRusso, M. Murtaza, Evaluation of pre-analytical factors affecting plasma DNA analysis. Scie Rep 8, 7375 (2018)CrossRef
63.
Y.Y. Lui, K.W. Chik, R.W. Chiu, C.Y. Ho, C.W. Lam, Y.M. Lo, Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 48, 421–427 (2002)PubMed
64.
M. Jung, S. Klotzek, M. Lewandowski, M. Fleischhacker, K. Jung, Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 49, 1028–1029 (2003)CrossRefPubMed
65.
N.Y. Lam, T.H. Rainer, R.W. Chiu, Y.M. Lo, Edta is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem 50, 256–257 (2004)CrossRefPubMed
66.
K.C. Chan, S.W. Yeung, W.B. Lui, T.H. Rainer, Y.M. Lo, Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem 51, 781–784 (2005)CrossRefPubMed
67.
R.E. Board, V.S. Williams, L. Knight, J. Shaw, A. Greystoke, M. Ranson, C. Dive, F.H. Blackhall, A. Hughes, Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann N Y Acad Sci 1137, 98–107 (2008)CrossRefPubMed
68.
S.E. Norton, K.K. Luna, J.M. Lechner, J. Qin, M.R. Fernando, A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device. J Clin Lab Anal 27, 305–311 (2013)CrossRefPubMedPubMedCentral
69.
M.R. Fernando, K. Chen, S. Norton, G. Krzyzanowski, D. Bourne, B. Hunsley, W.L. Ryan, C. Bassett, A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage. Prenat Diagn 30, 418–424 (2010)PubMed
70.
M. Hidestrand, R. Stokowski, K. Song, A. Oliphant, J. Deavers, M. Goetsch, P. Simpson, R. Kuhlman, M. Ames, M. Mitchell, A. Tomita-Mitchell, Influence of temperature during transportation on cell-free DNA analysis. Fetal Diagn Ther 31, 122–128 (2012)CrossRefPubMed
71.
Q. Kang, N.L. Henry, C. Paoletti, H. Jiang, P. Vats, A.M. Chinnaiyan, D.F. Hayes, S.D. Merajver, J.M. Rae, M. Tewari, Comparative analysis of circulating tumor DNA stability in k3edta, streck, and cellsave blood collection tubes. Clin Biochem 49, 1354–1360 (2016)CrossRefPubMed
72.
I. Medina Diaz, A. Nocon, D.H. Mehnert, J. Fredebohm, F. Diehl, F. Holtrup, Performance of streck cfdna blood collection tubes for liquid biopsy testing. PloS One 11, e0166354 (2016)CrossRefPubMedPubMedCentral
73.
E. Beutler, T. Gelbart, W. Kuhl, Interference of heparin with the polymerase chain reaction. Biotechniques 9, 166 (1990)PubMed
74.
C. Bettegowda, M. Sausen, R.J. Leary, I. Kinde, Y. Wang, N. Agrawal, B.R. Bartlett, H. Wang, B. Luber, R.M. Alani, E.S. Antonarakis, N.S. Azad, A. Bardelli, H. Brem, J.L. Cameron, C.C. Lee, L.A. Fecher, G.L. Gallia, P. Gibbs, D. Le, R.L. Giuntoli, M. Goggins, M.D. Hogarty, M. Holdhoff, S.-M. Hong, Y. Jiao, H.H. Juhl, J.J. Kim, G. Siravegna, D.A. Laheru, C. Lauricella, M. Lim, E.J. Lipson, S.K.N. Marie, G.J. Netto, K.S. Oliner, A. Olivi, L. Olsson, G.J. Riggins, A. Sartore-Bianchi, K. Schmidt, I.-M. Shih, S.M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie, T.T. Harkins, S. Veronese, T.-L. Wang, J.D. Weingart, C.L. Wolfgang, L.D. Wood, D. Xing, R.H. Hruban, J. Wu, P.J. Allen, C.M. Schmidt, M.A. Choti, V.E. Velculescu, K.W. Kinzler, B. Vogelstein, N. Papadopoulos, L.A. Diaz, Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6, 224ra224–224ra224 (2014)CrossRef
75.
A.A. Azad, S.V. Volik, A.W. Wyatt, A. Haegert, S. Le Bihan, R.H. Bell, S.A. Anderson, B. McConeghy, R. Shukin, J. Bazov, J. Youngren, P. Paris, G. Thomas, E.J. Small, Y. Wang, M.E. Gleave, C.C. Collins, K.N. Chi, Androgen receptor gene aberrations in circulating cell-free DNA: Biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 21, 2315–2324 (2015)CrossRefPubMed
76.
D. Charcon-Cortes, L.R. Griffiths, Methods for extracting genomic DNA from whole blood samples: Current perspectives. Br J Appl Sci Technol 2, 1–9 (2014)
77.
C.J. Jorgez, D.D. Dang, J.L. Simpson, D.E. Lewis, F.Z. Bischoff, Quantity versus quality: Optimal methods for cell-free DNA isolation from plasma of pregnant women. Genet Med 8, 615–619 (2006)CrossRefPubMed
78.
A. Psifidi, C.I. Dovas, G. Bramis, T. Lazou, C.L. Russel, G. Arsenos, G. Banos, Comparison of eleven methods for genomic DNA extraction suitable for large-scale whole-genome genotyping and long-term DNA banking using blood samples. PloS One 10, e0115960 (2015)CrossRefPubMedPubMedCentral
79.
A.S. Devonshire, A.S. Whale, A. Gutteridge, G. Jones, S. Cowen, C.A. Foy, J.F. Huggett, Towards standardisation of cell-free DNA measurement in plasma: Controls for extraction efficiency, fragment size bias and quantification. Anal Bional Chem 406, 6499–6512 (2014)CrossRef
80.
J.L. Sherwood, C. Corcoran, H. Brown, A.D. Sharpe, M. Musilova, A. Kohlmann, Optimised pre-analytical methods improve kras mutation detection in circulating tumour DNA (ctdna) from patients with non-small cell lung cancer (nsclc). PloS One 11, e0150197 (2016)CrossRefPubMedPubMedCentral
81.
J.-H. Lee, Y. Park, J.R. Choi, E.K. Lee, H.-S. Kim, Comparisons of three automated systems for genomic DNA extraction in a clinical diagnostic laboratory. Yonsei Med J 51, 104–110 (2010)CrossRefPubMed
82.
L. Sorber, K. Zwaenepoel, V. Deschoolmeester, G. Roeyen, F. Lardon, C. Rolfo, P. Pauwels, A comparison of cell-free DNA isolation kits: Isolation and quantification of cell-free DNA in plasma. J Mol Diagn 19, 162–168 (2017)CrossRefPubMed
83.
A. Jena, Pme free-circulating DNA extraction kit (2016)
84.
C. Gaillard, F. Strauss, Avoiding adsorption of DNA to polypropylene tubes and denaturation of short DNA fragments. Technical Tips Online 3, 63–65 (1998)CrossRef
85.
M. Lecerf, J.L. Goff, Use of eppendorf lobind® tubes to consistently prepare and store standard panels for real-time pcr absolute quantifications (2010)
86.
E. Heitzer, P. Ulz, J. Belic, S. Gutschi, F. Quehenberger, K. Fischereder, T. Benezeder, M. Auer, C. Pischler, S. Mannweiler, Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 5, 30 (2013)CrossRefPubMedPubMedCentral
87.
N. Van Roy, M. Van Der Linden, B. Menten, A. Dheedene, C. Vandeputte, J. Van Dorpe, G. Laureys, M. Renard, T. Sante, T. Lammens, B. De Wilde, F. Speleman, K. De Preter, Shallow whole genome sequencing on circulating cell-free DNA allows reliable noninvasive copy-number profiling in neuroblastoma patients. Clin Cancer Res 23, 6305–6314 (2017)CrossRefPubMed
88.
T. Forshew, M. Murtaza, C. Parkinson, D. Gale, D.W. Tsui, F. Kaper, S.J. Dawson, A.M. Piskorz, M. Jimenez-Linan, D. Bentley, Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4, 136 (2012)CrossRef
89.
X.W. Yongqian Shu, X. Tong, X. Wang, Z. Chang, Y. Mao, X. Chen, J. Sun, Z. Wang, Z. Hong, L. Zhu, C. Zhu, J. Chen, Y. Liang, H. Shao, Y.W. Shao, Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep 7, 583 (2017)CrossRefPubMedPubMedCentral
90.
A.A. Chaudhuri, M.S. Binkley, E.C. Osmundson, A.A. Alizadeh, M. Diehn, Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA. Semin Radiat Oncol 25, 305–312 (2015)CrossRefPubMedPubMedCentral
91.
I. Kinde, J. Wu, N. Papadopoulos, K.W. Kinzler, B. Vogelstein, Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 108, 9530–9535 (2011)CrossRefPubMedPubMedCentral
92.
A.M. Newman, S.V. Bratman, J. To, J.F. Wynne, N.C.W. Eclov, L.A. Modlin, C.L. Liu, J.W. Neal, H.A. Wakelee, R.E. Merritt, J.B. Shrager, B.W. Loo Jr., A.A. Alizadeh, M. Diehn, An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20, 548–554 (2014)CrossRefPubMedPubMedCentral
93.
S.V. Bratman, A.M. Newman, A.A. Alizadeh, M. Diehn, Potential clinical utility of ultrasensitive circulating tumor DNA detection with capp-seq. Expert Rev Mol Diagn 15, 715–719 (2015)CrossRefPubMedPubMedCentral
94.
J.S. Bhangu, H. Taghizadeh, T. Braunschmid, T. Bachleitner-Hofmann, C. Mannhalter, Circulating cell-free DNA in plasma of colorectal cancer patients - a potential biomarker for tumor burden. Surg Oncol 26, 395–401 (2017)CrossRefPubMed
95.
E. Gormally, P. Vineis, G. Matullo, F. Veglia, E. Caboux, E. Le Roux, M. Peluso, S. Garte, S. Guarrera, A. Munnia, L. Airoldi, H. Autrup, C. Malaveille, A. Dunning, K. Overvad, A. Tjønneland, E. Lund, F. Clavel-Chapelon, H. Boeing, A. Trichopoulou, D. Palli, V. Krogh, R. Tumino, S. Panico, H.B. Bueno-de-Mesquita, P.H. Peeters, G. Pera, C. Martinez, M. Dorronsoro, A. Barricarte, C. Navarro, J.R. Quirós, G. Hallmans, N.E. Day, T.J. Key, R. Saracci, R. Kaaks, E. Riboli, P. Hainaut, Tp53 and kras2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study. Cancer Res 66, 6871–6876 (2006)CrossRefPubMed
96.
L. Mao, R.H. Hruban, J.O. Boyle, M. Tockman, D. Sidransky, Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54, 1634–1637 (1994)PubMed
97.
S. Salvi, G. Gurioli, U. De Giorgi, V. Conteduca, G. Tedaldi, D. Calistri, V. Casadio, Cell-free DNA as a diagnostic marker for cancer: Current insights. Onco targets Ther 9, 6549–6559 (2016)CrossRefPubMedPubMedCentral
98.
I. Martincorena, A. Roshan, M. Gerstung, P. Ellis, P. Van Loo, S. McLaren, D.C. Wedge, A. Fullam, L.B. Alexandrov, J.M. Tubio, L. Stebbings, A. Menzies, S. Widaa, M.R. Stratton, P.H. Jones, P.J. Campbell, High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880–886 (2015)CrossRefPubMedPubMedCentral
99.
L. Fernandez-Cuesta, S. Perdomo, P.H. Avogbe, N. Leblay, T.M. Delhomme, V. Gaborieau, B. Abedi-Ardekani, E. Chanudet, M. Olivier, D. Zaridze, A. Mukeria, M. Vilensky, I. Holcatova, J. Polesel, L. Simonato, C. Canova, P. Lagiou, C. Brambilla, E. Brambilla, G. Byrnes, G. Scelo, F. Le Calvez-Kelm, M. Foll, J.D. McKay, P. Brennan, Identification of circulating tumor DNA for the early detection of small-cell lung cancer. EBioMedicine 10, 117–123 (2016)CrossRefPubMedPubMedCentral
100.
J.D. Cohen, L. Li, Y. Wang, C. Thoburn, B. Afsari, L. Danilova, C. Douville, A.A. Javed, F. Wong, A. Mattox, R.H. Hruban, C.L. Wolfgang, M.G. Goggins, M. Dal Molin, T.-L. Wang, R. Roden, A.P. Klein, J. Ptak, L. Dobbyn, J. Schaefer, N. Silliman, M. Popoli, J.T. Vogelstein, J.D. Browne, R.E. Schoen, R.E. Brand, J. Tie, P. Gibbs, H.-L. Wong, A.S. Mansfield, J. Jen, S.M. Hanash, M. Falconi, P.J. Allen, S. Zhou, C. Bettegowda, L.A. Diaz, C. Tomasetti, K.W. Kinzler, B. Vogelstein, A.M. Lennon, N. Papadopoulos, Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926–930 (2018)CrossRefPubMedPubMedCentral
101.
K. Birkenkamp-Demtroder, I. Nordentoft, E. Christensen, S. Hoyer, T. Reinert, S. Vang, M. Borre, M. Agerbaek, J.B. Jensen, T.F. Orntoft, L. Dyrskjot, Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 70, 75–82 (2016)CrossRefPubMed
102.
F.A. Greco, K. Oien, M. Erlander, R. Osborne, G. Varadhachary, J. Bridgewater, D. Cohen, H. Wasan, Cancer of unknown primary: Progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 23, 298–304 (2012)CrossRefPubMed
103.
M.W. Snyder, M. Kircher, A.J. Hill, R.M. Daza, J. Shendure, Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57–68 (2016)CrossRefPubMedPubMedCentral
104.
M.R. Openshaw, R.A. Harvey, N.J. Sebire, B. Kaur, N. Sarwar, M.J. Seckl, R.A. Fisher, Circulating cell free DNA in the diagnosis of trophoblastic tumors. EBioMedicine 4, 146–152 (2016)CrossRefPubMed
105.
J.-Y. Douillard, G. Ostoros, M. Cobo, T. Ciuleanu, R. Cole, G. McWalter, J. Walker, S. Dearden, A. Webster, T. Milenkova, R. McCormack, Gefitinib treatment in egfr mutated caucasian nsclc: Circulating-free tumor DNA as a surrogate for determination of egfr status. J Thorac Oncol 9, 1345–1353 (2014)CrossRefPubMedPubMedCentral
106.
M.F. Sanmamed, S. Fernandez-Landazuri, C. Rodriguez, R. Zarate, M.D. Lozano, L. Zubiri, J.L. Perez-Gracia, S. Martin-Algarra, A. Gonzalez, Quantitative cell-free circulating brafv600e mutation analysis by use of droplet digital pcr in the follow-up of patients with melanoma being treated with braf inhibitors. Clin Chem 61, 297–304 (2015)CrossRefPubMed
107.
K.L. Spindler, N. Pallisgaard, I. Vogelius, A. Jakobsen, Quantitative cell-free DNA, kras, and braf mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 18, 1177–1185 (2012)CrossRefPubMed
108.
A.R. Thierry, F. Mouliere, S. El Messaoudi, C. Mollevi, E. Lopez-Crapez, F. Rolet, B. Gillet, C. Gongora, P. Dechelotte, B. Robert, M. Del Rio, P.J. Lamy, F. Bibeau, M. Nouaille, V. Loriot, A.S. Jarrousse, F. Molina, M. Mathonnet, D. Pezet, M. Ychou, Clinical validation of the detection of kras and braf mutations from circulating tumor DNA. Nat Med 20, 430–435 (2014)CrossRefPubMed
109.
A. Santiago-Walker, R. Gagnon, J. Mazumdar, M. Casey, G.V. Long, D. Schadendorf, K. Flaherty, R. Kefford, A. Hauschild, P. Hwu, P. Haney, A. O'Hagan, J. Carver, V. Goodman, J. Legos, A.M. Martin, Correlation of braf mutation status in circulating-free DNA and tumor and association with clinical outcome across four brafi and meki clinical trials. Clin Cancer Res 22, 567–574 (2016)CrossRefPubMed
110.
L. De Mattos-Arruda, B. Weigelt, J. Cortes, H.H. Won, C.K. Ng, P. Nuciforo, F.C. Bidard, C. Aura, C. Saura, V. Peg, S. Piscuoglio, M. Oliveira, Y. Smolders, P. Patel, L. Norton, J. Tabernero, M.F. Berger, J. Seoane, J.S. Reis-Filho, Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle. Ann Oncol 25, 1729–1735 (2014)CrossRefPubMedPubMedCentral
111.
J.A. García-Saenz, P. Ayllón, M. Laig, D. Acosta-Eyzaguirre, M. García-Esquinas, M. Montes, J. Sanz, M. Barquín, F. Moreno, V. Garcia-Barberan, E. Díaz-Rubio, T. Caldes, A. Romero, Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer 17, 210 (2017)CrossRefPubMedPubMedCentral
112.
D.J. McBride, A.K. Orpana, C. Sotiriou, H. Joensuu, P.J. Stephens, L.J. Mudie, E. Hämäläinen, L.A. Stebbings, L.C. Andersson, A.M. Flanagan, V. Durbecq, M. Ignatiadis, O. Kallioniemi, C.A. Heckman, K. Alitalo, H. Edgren, P.A. Futreal, M.R. Stratton, P.J. Campbell, Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 49, 1062–1069 (2010)CrossRefPubMedPubMedCentral
113.
X. Yi, J. Ma, Y. Guan, R. Chen, L. Yang, X. Xia, The feasibility of using mutation detection in ctdna to assess tumor dynamics. Int J Cancer 140, 2642–2647 (2017)CrossRefPubMedPubMedCentral
114.
C.A. Parkinson, D. Gale, A.M. Piskorz, H. Biggs, C. Hodgkin, H. Addley, S. Freeman, P. Moyle, E. Sala, K. Sayal, K. Hosking, I. Gounaris, M. Jimenez-Linan, H.M. Earl, W. Qian, N. Rosenfeld, J.D. Brenton, Exploratory analysis of tp53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: A retrospective study. PLoS Medicine 13, e1002198 (2016)CrossRefPubMedPubMedCentral
115.
S.-J. Dawson, D.W.Y. Tsui, M. Murtaza, H. Biggs, O.M. Rueda, S.-F. Chin, M.J. Dunning, D. Gale, T. Forshew, B. Mahler-Araujo, S. Rajan, S. Humphray, J. Becq, D. Halsall, M. Wallis, D. Bentley, C. Caldas, N. Rosenfeld, Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368, 1199–1209 (2013)CrossRefPubMed
116.
B. Ai, H. Liu, Y. Huang, P. Peng, Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget 7, 44583–44595 (2016)CrossRefPubMedPubMedCentral
117.
S. Basnet, Z.-y. Zhang, W.-q. Liao, S.-h. Li, P.-s. Li, H.-y. Ge, The prognostic value of circulating cell-free DNA in colorectal cancer: A meta-analysis. J Cancer 7, 1105–1113 (2016)CrossRefPubMedPubMedCentral
118.
Z. Yi, B. Liu, X. Guan, F. Ma, Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis. Mol Clin Oncol 7, 167–172 (2017)PubMedPubMedCentral
119.
C. Bedin, M.V. Enzo, P. Del Bianco, S. Pucciarelli, D. Nitti, M. Agostini, Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. International Journal of Cancer 140, 1888–1898 (2017)CrossRefPubMed
120.
J.H. No, K. Kim, K.H. Park, Y.B. Kim, Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. Anticancer Res 32, 3467–3471 (2012)PubMed
121.
G.R. Oxnard, K.S. Thress, R.S. Alden, R. Lawrance, C.P. Paweletz, M. Cantarini, J.C. Yang, J.C. Barrett, P.A. Janne, Association between plasma genotyping and outcomes of treatment with osimertinib (azd9291) in advanced non-small-cell lung cancer. J Clin Oncol 34, 3375–3382 (2016)CrossRefPubMedPubMedCentral
122.
123.
O.A. Zill, K.C. Banks, S.R. Fairclough, S. Mortimer, J.V. Vowles, R. Mokhtari, D.R. Gandara, P.C. Mack, J.I. Odegaard, R.J. Nagy, A.M. Baca, H. Eltoukhy, D.I. Chudova, R.B. Lanman, A. Talasaz, The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin Cancer Res 24, 3528–3538 (2018)CrossRefPubMed
124.
D.K. Lee, J.H. Park, J.H. Kim, S.J. Lee, M.K. Jo, M.C. Gil, K.H. Song, J.W. Park, Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. Korean J Radiol 51, 358–361 (2010)
125.
A.H. Bryce, J.J. Alumkal, A. Armstrong, C.S. Higano, P. Iversen, C.N. Sternberg, D. Rathkopf, Y. Loriot, J. de Bono, B. Tombal, S. Abhyankar, P. Lin, A. Krivoshik, D. Phung, T.M. Beer, Radiographic progression with nonrising psa in metastatic castration-resistant prostate cancer: Post hoc analysis of prevail. Prostate Cancer Prostatic Dis 20, 221–227 (2017)CrossRefPubMedPubMedCentral
126.
T.A. Stamey, N. Yang, A.R. Hay, J.E. McNeal, F.S. Freiha, E. Redwine, Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Eng J Med 317, 909–916 (1987)CrossRefPubMed
127.
J. Lokich, S. Ellenberg, B. Gerson, W.E. Knox, N. Zamcheck, Plasma clearance of carcinoembryonic antigen following hepatic metastatectomy. J Clin Oncol 2, 462–465 (1984)CrossRefPubMed
128.
E.S. Gray, H. Rizos, A.L. Reid, S.C. Boyd, M.R. Pereira, J. Lo, V. Tembe, J. Freeman, J.H. Lee, R.A. Scolyer, K. Siew, C. Lomma, A. Cooper, M.A. Khattak, T.M. Meniawy, G.V. Long, M.S. Carlino, M. Millward, M. Ziman, Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6, 42008–42018 (2015)PubMedPubMedCentral
129.
S.-J. Dawson, D.W.Y. Tsui, M. Murtaza, H. Biggs, O.M. Rueda, S.-F. Chin, M.J. Dunning, D. Gale, T. Forshew, B. Mahler-Araujo, S. Rajan, S. Humphray, J. Becq, D. Halsall, M. Wallis, D. Bentley, C. Caldas, N. Rosenfeld, Analysis of circulating tumor DNA to monitor metastatic breast cancer. New Eng J Med 368, 1199–1209 (2013)CrossRefPubMed
130.
A. Ashida, K. Sakaizawa, H. Uhara, R. Okuyama, Circulating tumour DNA for monitoring treatment response to anti-pd-1 immunotherapy in melanoma patients. Acta Derm Venereol 97, 1212–1218 (2017)CrossRefPubMed
131.
J. Tie, I. Kinde, Y. Wang, H.L. Wong, J. Roebert, M. Christie, M. Tacey, R. Wong, M. Singh, C.S. Karapetis, J. Desai, B. Tran, R.L. Strausberg, L.A. Diaz Jr., N. Papadopoulos, K.W. Kinzler, B. Vogelstein, P. Gibbs, Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 26, 1715–1722 (2015)CrossRefPubMedPubMedCentral
132.
L. Xi, T.H. Pham, E.C. Payabyab, R.M. Sherry, S.A. Rosenberg, M. Raffeld, Circulating tumor DNA as an early indicator of response to t-cell transfer immunotherapy in metastatic melanoma. Clin Cancer Res 22, 5480–5486 (2016)CrossRefPubMedPubMedCentral
133.
G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre, N. Snyder, S. Sarkar, Drug resistance in cancer: An overview. Cancers 6, 1769–1792 (2014)CrossRefPubMedPubMedCentral
134.
E. Kirkizlar, B. Zimmermann, T. Constantin, R. Swenerton, B. Hoang, N. Wayham, J.E. Babiarz, Z. Demko, R.J. Pelham, S. Kareht, A.L. Simon, K.N. Jinnett, M. Rabinowitz, S. Sigurjonsson, M. Hill, Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed pcr methodology. Transl Oncol 8, 407–416 (2015)CrossRefPubMedPubMedCentral
135.
J.S. Frenel, S. Carreira, J. Goodall, D. Roda, R. Perez-Lopez, N. Tunariu, R. Riisnaes, S. Miranda, I. Figueiredo, D. Nava-Rodrigues, A. Smith, C. Leux, I. Garcia-Murillas, R. Ferraldeschi, D. Lorente, J. Mateo, M. Ong, T.A. Yap, U. Banerji, D. Gasi Tandefelt, N. Turner, G. Attard, J.S. de Bono, Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration. Clin Cancer Res 21, 4586–4596 (2015)CrossRefPubMedPubMedCentral
136.
G. Siravegna, B. Mussolin, M. Buscarino, G. Corti, A. Cassingena, G. Crisafulli, A. Ponzetti, C. Cremolini, A. Amatu, C. Lauricella, S. Lamba, S. Hobor, A. Avallone, E. Valtorta, G. Rospo, E. Medico, V. Motta, C. Antoniotti, F. Tatangelo, B. Bellosillo, S. Veronese, A. Budillon, C. Montagut, P. Racca, S. Marsoni, A. Falcone, R.B. Corcoran, F. Di Nicolantonio, F. Loupakis, S. Siena, A. Sartore-Bianchi, A. Bardelli, Clonal evolution and resistance to egfr blockade in the blood of colorectal cancer patients. Nat Med 21, 827 (2015)
137.
R. Lebofsky, C. Decraene, V. Bernard, M. Kamal, A. Blin, Q. Leroy, T. Rio Frio, G. Pierron, C. Callens, I. Bieche, A. Saliou, J. Madic, E. Rouleau, F.-C. Bidard, O. Lantz, M.-H. Stern, C. Le Tourneau, J.-Y. Pierga, Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 9, 783–790 (2015)CrossRefPubMed
138.
K.S. Thress, R. Brant, T.H. Carr, S. Dearden, S. Jenkins, H. Brown, T. Hammett, M. Cantarini, J.C. Barrett, Egfr mutation detection in ctdna from nsclc patient plasma: A cross-platform comparison of leading technologies to support the clinical development of azd9291. Lung Cancer 90, 509–515 (2015)CrossRefPubMed
139.
B.S. Sorensen, L. Wu, W. Wei, J. Tsai, B. Weber, E. Nexo, P. Meldgaard, Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 120, 3896–3901 (2014)CrossRefPubMed
140.
G.R. Oxnard, C.P. Paweletz, Y. Kuang, S.L. Mach, A. O'Connell, M.M. Messineo, J.J. Luke, M. Butaney, P. Kirschmeier, D.M. Jackman, P.A. Janne, Noninvasive detection of response and resistance in egfr-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20, 1698–1705 (2014)CrossRefPubMedPubMedCentral
141.
A.W. Wyatt, A.A. Azad, S.V. Volik, M. Annala, K. Beja, B. McConeghy, A. Haegert, E.W. Warner, F. Mo, S. Brahmbhatt, R. Shukin, S. Le Bihan, M.E. Gleave, M. Nykter, C.C. Collins, K.N. Chi, Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol 2, 1598–1606 (2016)CrossRefPubMedPubMedCentral
142.
M. Annala, G. Vandekerkhove, D. Khalaf, S. Taavitsainen, K. Beja, E.W. Warner, K. Sunderland, C. Kollmannsberger, B.J. Eigl, D. Finch, C.D. Oja, J. Vergidis, M. Zulfiqar, A.A. Azad, M. Nykter, M.E. Gleave, A.W. Wyatt, K.N. Chi, Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov 8, 444–457 (2018)CrossRefPubMed
143.
G. Gremel, R.J. Lee, M.R. Girotti, A.K. Mandal, S. Valpione, G. Garner, M. Ayub, S. Wood, D.G. Rothwell, A. Fusi, A. Wallace, G. Brady, C. Dive, N. Dhomen, P. Lorigan, R. Marais, Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. Ann Oncol 27, 1959–1965 (2016)CrossRefPubMedPubMedCentral
144.
L.A. Diaz, R. Williams, J. Wu, I. Kinde, J.R. Hecht, J. Berlin, B. Allen, I. Bozic, J.G. Reiter, M.A. Nowak, K.W. Kinzler, K.S. Oliner, B. Vogelstein, The molecular evolution of acquired resistance to targeted egfr blockade in colorectal cancers. Nature 486, 537–540 (2012)CrossRefPubMedPubMedCentral
145.
J. Tie, Y. Wang, C. Tomasetti, L. Li, S. Springer, I. Kinde, N. Silliman, M. Tacey, H.L. Wong, M. Christie, S. Kosmider, I. Skinner, R. Wong, M. Steel, B. Tran, J. Desai, I. Jones, A. Haydon, T. Hayes, T.J. Price, R.L. Strausberg, L.A. Diaz Jr., N. Papadopoulos, K.W. Kinzler, B. Vogelstein, P. Gibbs, Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage ii colon cancer. Sci Transl Med 8, 346ra392 (2016)CrossRef
146.
L. Kubiczkova-Besse, D. Drandi, L. Sedlarikova, S. Oliva, M. Gambella, P. Omedè, Z. Adam, L. Pour, S. Sevcikova, M. Boccadoro, A. Palumbo, R. Hajek, Cell-free DNA for minimal residual disease monitoring in multiple myeloma patients. Blood 124, 3423 (2014)
147.
L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, G.M. Clark, REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 22, 387–391 (2005)CrossRef
148.
D.G. Altman, L.M. McShane, W. Sauerbrei, S.E. Taube, Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 9, e1001216 (2012)CrossRefPubMedPubMedCentral
149.
D.S. Tan, G.V. Thomas, M.D. Garrett, U. Banerji, J.S. de Bono, S.B. Kaye, P. Workman, Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 15, 406–420 (2009)CrossRefPubMed
150.
J. Cummings, F. Raynaud, L. Jones, R. Sugar, C. Dive, Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer 26, 1313–1317 (2010)CrossRef
151.
D.L. Jardim, M. Schwaederle, D.S. Hong, R. Kurzrock, An appraisal of drug development timelines in the Era of precision oncology. Oncotarget 16, 53037–53046 (2016)
152.
E. Heitzer, P. Ulz, J. Belic, S. Gutschi, F. Quehenberger, K. Fischereder, T. Benezeder, M. Auer, C. Pischler, S. Mannweiler, M. Pichler, F. Eisner, M. Haeusler, S. Riethdorf, K. Pantel, H. Samonigg, G. Hoefler, H. Augustin, J.B. Geigl, M.R. Speicher, Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 5, 30 (2013)CrossRefPubMedPubMedCentral
153.
R.J. Leary, M. Sausen, I. Kinde, N. Papadopoulos, J.D. Carpten, D. Craig, J. O'Shaughnessy, K.W. Kinzler, G. Parmigiani, B. Vogelstein, L.A. Diaz Jr., V.E. Velculescu, Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4, 162ra154 (2012)CrossRefPubMedPubMedCentral
154.
J.A. Vendrell, F.T. Mau-Them, B. Béganton, S. Godreuil, P. Coopman, J. Solassol, Circulating cell free tumor DNA detection as a routine tool for lung cancer patient management. Int J Mol Sci 18, 264 (2017)CrossRefPubMedCentral
155.
R. Salani, C.-L. Chang, L. Cope, T.-L. Wang, Digital karyotyping: An update of its applications in cancer. Mol Diagn Ther 10, 231 (2006)CrossRefPubMed
156.
M. Murtaza, S.J. Dawson, D.W. Tsui, D. Gale, T. Forshew, A.M. Piskorz, C. Parkinson, S.F. Chin, Z. Kingsbury, A.S. Wong, F. Marass, S. Humphray, J. Hadfield, D. Bentley, T.M. Chin, J.D. Brenton, C. Caldas, N. Rosenfeld, Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112 (2013)CrossRefPubMed
157.
C. Vnencak-Jones, M. Berger, W. Pao. Types of molecular tumor testing (2016)
158.
A. Narayan, N.J. Carriero, S.N. Gettinger, J. Kluytenaar, K.R. Kozak, T.I. Yock, N.E. Muscato, P. Ugarelli, R.H. Decker, A.A. Patel, Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 72, 3492–3498 (2012)CrossRefPubMedPubMedCentral
159.
D. Gale, V. Plagnol, A. Lawson, M. Pugh, S. Smalley, K. Howarth, M. Madi, B. Durham, V. Kumanduri, K. Lo, J. Clark, E. Green, N. Rosenfeld, T. Forshew, Abstract 3639: Analytical performance and validation of an enhanced tam-seq circulating tumor DNA sequencing assay. Cancer Res 76, 3639–3639 (2016)
160.
A.M. Newman, A.F. Lovejoy, D.M. Klass, D.M. Kurtz, J.J. Chabon, F. Scherer, H. Stehr, C.L. Liu, S.V. Bratman, C. Say, L. Zhou, J.N. Carter, R.B. West, G.W. Sledge, J.B. Shrager, B.W. Loo Jr., J.W. Neal, H.A. Wakelee, M. Diehn, A.A. Alizadeh, Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnol 34, 547–555 (2016)CrossRef
161.
R.B. Lanman, S.A. Mortimer, O.A. Zill, D. Sebisanovic, R. Lopez, S. Blau, E.A. Collisson, S.G. Divers, D.S. Hoon, E.S. Kopetz, J. Lee, P.G. Nikolinakos, A.M. Baca, B.G. Kermani, H. Eltoukhy, A. Talasaz, Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PloS One 10, e0140712 (2015)CrossRefPubMedPubMedCentral
162.
F. Rothe, J.F. Laes, D. Lambrechts, D. Smeets, D. Vincent, M. Maetens, D. Fumagalli, S. Michiels, S. Drisis, C. Moerman, J.P. Detiffe, D. Larsimont, A. Awada, M. Piccart, C. Sotiriou, M. Ignatiadis, Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 25, 1959–1965 (2014)CrossRefPubMed
163.
H.R. Kim, S.Y. Lee, D.S. Hyun, M.K. Lee, H.K. Lee, C.M. Choi, S.H. Yang, Y.C. Kim, Y.C. Lee, S.Y. Kim, S.H. Jang, J.C. Lee, K.Y. Lee, Detection of egfr mutations in circulating free DNA by pna-mediated pcr clamping. J Exp Clin Cancer Res 32, 50 (2013)CrossRefPubMedPubMedCentral
164.
D. Sefrioui, F. Mauger, L. Leclere, L. Beaussire, F. Di Fiore, J.-F. Deleuze, N. Sarafan-Vasseur, J. Tost, Comparison of the quantification of kras mutations by digital pcr and e-ice-cold-pcr in circulating-cell-free DNA from metastatic colorectal cancer patients. Clinica Chimica Acta 465, 1–4 (2017)CrossRef
165.
K. Watanabe, T. Fukuhara, Y. Tsukita, M. Morita, A. Suzuki, N. Tanaka, H. Terasaki, T. Nukiwa, M. Maemondo, Egfr mutation analysis of circulating tumor DNA using an improved pna-lna pcr clamp method. Can Respir J 2016, 1–7 (2016)CrossRef
166.
K. Taniguchi, J. Uchida, K. Nishino, T. Kumagai, T. Okuyama, J. Okami, M. Higashiyama, K. Kodama, F. Imamura, K. Kato, Quantitative detection of egfr mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 17, 7808–7815 (2011)CrossRefPubMed
167.
T.K. Yung, K.C. Chan, T.S. Mok, J. Tong, K.F. To, Y.M. Lo, Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital pcr in non-small cell lung cancer patients. Clin Cancer Res 15, 2076–2084 (2009)CrossRefPubMed
168.
X. Chai, P. Ren, B. Wei, J. Ma, L. Mai, D.S. Cram, Y. Song, Y. Guo, A comparative study of egfr oncogenic mutations in matching tissue and plasma samples from patients with advanced non-small cell lung carcinoma. Clinica Chimica Acta 457, 106–111 (2016)CrossRef
169.
J. Luo, L. Shen, D. Zheng, Diagnostic value of circulating free DNA for the detection of egfr mutation status in nsclc: A systematic review and meta-analysis. Sci Rep 4, 6269 (2014)CrossRefPubMedPubMedCentral
170.
E. Kidess, K. Heirich, M. Wiggin, V. Vysotskaia, B.C. Visser, A. Marziali, B. Wiedenmann, J.A. Norton, M. Lee, S.S. Jeffrey, G.A. Poultsides, Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget 6, 2549–2561 (2015)CrossRefPubMed
171.
I. Ladas, M. Fitarelli-Kiehl, C. Song, V.A. Adalsteinsson, H.A. Parsons, N.U. Lin, N. Wagle, G.M. Makrigiorgos, Multiplexed elimination of wild-type DNA and high-resolution melting prior to targeted resequencing of liquid biopsies. Clin Chem 63, 1605–1613 (2017)CrossRefPubMedPubMedCentral
Metadata
Title
Cell-free DNA in cancer: current insights
Authors
Heidi Fettke
Edmond M. Kwan
Arun A. Azad
Publication date
01-02-2019
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 1/2019
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-018-0413-5

Other articles of this Issue 1/2019

Cellular Oncology 1/2019 Go to the issue

Report

Molecular features unique to glioblastoma radiation resistant residual cells may affect patient outcome - a short report

Original Paper

CCL18 secreted from M2 macrophages promotes migration and invasion via the PI3K/Akt pathway in gallbladder cancer

Review

Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer

Original Paper

SOX3 can promote the malignant behavior of glioblastoma cells

Original Paper

S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells

Original Paper

Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits